Home > Insider Trading > Filing (0001193805-10-000972)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1019695	Arqule Inc	ARQL	Pharmaceutical Preparations (2834)	043221586

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
918923	P L Fund Value Biotechnology	900 North Michigan Avenue Suite 1100 Chicago IL 60611	No	No	No	Yes
1055947	P/Il L Partners Bvf	900 North Michigan Avenue Suite 1100 Chicago IL 60611	No	No	Yes	No
1056807	Bvf Inc/Il	900 North Michigan Avenue Suite 1100 Chicago IL 60611	No	No	Yes	No
1102444	Biotechnology Value Fund Ii Lp	900 North Michigan Avenue Suite 1100 Chicago IL 60611	No	No	No	Yes
1132245	Bvf Investments Llc	900 North Michigan Avenue Suite 1100 Chicago IL 60611	No	No	No	Yes
1233840	N Mark Lampert	900 North Michigan Avenue Suite 1100 Chicago IL 60611	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2010-03-31	645,000	$6.24	7,919,073	No	4	S	Direct
Common Stock	Disposition	2010-03-31	447,000	$6.24	7,472,073	No	4	S	Direct
Common Stock	Disposition	2010-03-31	1,548,000	$6.24	5,924,073	No	4	S	Direct
Common Stock	Disposition	2010-04-01	272,000	$5.81	5,652,073	No	4	S	Direct
Common Stock	Disposition	2010-04-01	188,000	$5.81	5,464,073	No	4	S	Direct
Common Stock	Disposition	2010-04-01	653,000	$5.81	4,811,073	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	4,811,073	Indirect	General partner & manager of entities with direct ownership.
Common Stock	4,811,073	Indirect	General Partner of entity with indirect ownership.
Common Stock	4,811,073	Indirect	Sole shareholder & sole dir. of entity w/ indirect ownership.

Footnotes

Units may represent aggregation of daily trade activity. Details regarding individual execution amounts and prices are available upon request.
Shares directly beneficially owned by Biotechnology Value Fund, L.P. ("BVF")
Shares directly beneficially owned by Biotechnology Value Fund II, L.P. ("BVF II")
The shares of Common Stock are directly beneficially owned by BVF Investments, LLC ("BVFLLC"), a Delaware limited liability company. Pursuant to the operatingagreement of BVFLLC, BVF Partners, L.P., a Delaware limited partnership ("Partners") is authorized, among other things, to invest the contributed capital of SamanaCapital, L.P., the majority member of BVFLLC, in the shares of Common Stock and other securities and to vote, exercise or convert and dispose of such securities andis entitled to receive fees based on assets under management and, subject to certain exceptions, allocations based on realized and unrealized gains on such assets.
The shares of Common Stock are indirectly beneficially owned by Partners. Partners is the general partner of BVF and BVF II and is the manager of BVFLLC.
The shares of Common Stock are indirectly beneficially owned by BVF Inc., a Delaware corporation ("BVF Inc."). BVF Inc. is the general partner of Partners.
Mark N. Lampert is the sole shareholder, sole director, and an officer of BVF Inc.